Takahiro Kumode

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

Journal: The Lancet. Haematology

Published: March 31, 2026

Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.

Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.

Journal: Transplantation and cellular therapy

Published: March 13, 2026

Real-World Safety and Efficacy of Pola-R-CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients.

Real-World Safety and Efficacy of Pola-R-CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients.

Journal: Cancer science

Published: March 05, 2026

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.

Journal: International journal of clinical oncology

Published: January 06, 2026

Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma.

Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma.

Journal: International journal of clinical oncology

Published: October 29, 2025

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study.

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study.

Journal: International journal of hematology

Published: August 20, 2025

Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells.

Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells.

Journal: Current issues in molecular biology

Published: August 16, 2025

Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.

Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.

Journal: International journal of hematology

Published: July 28, 2025

Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR).

Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR).

Journal: International journal of hematology

Published: July 24, 2025

Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial.

Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial.

Journal: Leukemia & lymphoma

Published: July 09, 2025

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Journal: Lancet (London, England)

Published: March 26, 2025

Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.

Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.

Journal: International journal of clinical oncology

Published: March 13, 2025

Showing 1-12 of 37

Last Updated: 09/26/2026